Roadmaps to Regulation: New Psychoactive Substances

On 26 May 2016, the New Psychoactive Substances Act passed into UK law, rendering it illegal to buy, sell or supply any substance deemed to have psychoactive properties.

But what will happen to the public appetite for “legal highs,” and what will happen to the drugs themselves?

To mark the day, Amanda Feilding and the Beckley Foundation have released this chapter on NPS from our forthcoming report, “Roadmaps to Regulation: Cannabis, Psychedelics, MDMA and NPS.” The chapter explains the medical and social fallacies of applying a blanket ban to this vast array of chemically dissimilar substances, and strategises how we could legally regulate the unquellable market for NPS.

Screen Shot 2016-05-26 at 13.29.59

NPS in the Press: Amanda has shared her perspective on the myriad harms that this new legislation will bring with it in the Metro , Vice: Motherboard and the Mirror.


"Who would want N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide when they could legally purchase cannabis?"

Amanda Feilding

Roadmaps to Regulation: NPS Chapter (PDF)

NPS Chapter Executive Summary (PDF)

Roadmaps to Regulation: Cannabis, Psychedelics, MDMA, and NPS

Amanda Feilding (Coordinating Editor) and Nicola Singleton, with additional input from Alex Stevens, 2016

Read more

Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'

Addiction, 2012

Read more

Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans

PloS one, 2010

Read more

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series

Cephalalgia:an international journal of headache, 2010

Read more